ESPR
NEUTRALAt a glance
Key valuation, profitability, growth, and risk metrics.
AI Analysis
AI-powered fundamental assessment
Key Strengths
Key Risks
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Rule-based valuation (P/E + Graham).
- Insufficient data for clear positives.
Rule-based growth outlook.
- Revenue growth running at 143.7%.
Historical performance + price trend: Shares moved -91.3% over 5Y and +119.8% over 1Y.
- Insufficient data for clear positives.
- Thin profit margins.
Balance sheet & liquidity (Z-Score: N/A).
- Insufficient data for clear positives.
Dividend policy fallback.
- Insufficient data for clear positives.
- No regular dividend payments.
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for ESPR and closest competitors.
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
ESPR
Esperion Therapeutics, Inc.
Primary
|
-91.3% | +70.1% | +119.8% | -9.3% | -23.4% | -10.7% |
|
BVS
Bioventus Inc.
Peer
|
-36.8% | +662.1% | +6.9% | +32.9% | +2.7% | -3.2% |
|
AVNS
Avanos Medical, Inc.
Peer
|
-72.6% | -56.0% | -17.1% | +9.0% | +14.8% | +6.1% |
|
EMBC
Embecta Corp.
Peer
|
-78.3% | -65.2% | -18.7% | -34.0% | -3.8% | +1.0% |
|
AVR
Anteris Technologies Global Corp.
Peer
|
-8.8% | -8.8% | +40.4% | +17.2% | -21.5% | -6.6% |
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Valuation Metrics
Key valuation ratios and pricing indicators
Profitability
Profit margins and return metrics
Growth
Revenue and earnings growth rates
Financial Health
Balance sheet strength and liquidity metrics
Financial Statement Flow
Interactive flow visualization showing how money moves through the company Q4 2025
Quarterly Earnings History
EPS performance vs analyst estimates
Healthcare Sector Comparison
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
ESPR
Esperion Therapeutics, Inc.
|
NEUTRAL | $598.37M | - | -% | -5.6% | $2.33 | |
|
BVS
Bioventus Inc.
|
BEARISH | $595.53M | 26.79 | 13.2% | 4.0% | $8.84 | Compare |
|
AVNS
Avanos Medical, Inc.
|
BEARISH | $607.62M | - | -46.7% | -67.0% | $13.09 | Compare |
|
EMBC
Embecta Corp.
|
NEUTRAL | $525.87M | 3.73 | -% | 12.9% | $8.88 | Compare |
|
AVR
Anteris Technologies Global Corp.
|
BEARISH | $496.86M | - | -301.9% | -% | $5.11 | Compare |
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2026-03-17 | KOENIG SHELDON L | Chief Executive Officer | Sale | 25,578 | $69,547 |
| 2026-03-17 | LOOKER BENJAMIN | Officer | Sale | 5,708 | $15,429 |
| 2026-03-17 | HALLADAY BENJAMIN | Chief Financial Officer | Sale | 6,424 | $17,377 |
| 2026-03-13 | KOENIG SHELDON L | Chief Executive Officer | Stock Award | 723,760 | - |
| 2026-03-13 | LOOKER BENJAMIN | Officer | Stock Award | 300,840 | - |
| 2026-03-13 | HALLADAY BENJAMIN | Chief Financial Officer | Stock Award | 247,430 | - |
| 2026-01-20 | LOOKER BENJAMIN | General Counsel | Sale | 1,689 | $4,868 |
| 2025-12-17 | KOENIG SHELDON L | Chief Executive Officer | Sale | 48,244 | $177,200 |
| 2025-12-17 | LOOKER BENJAMIN | General Counsel | Sale | 6,517 | $23,898 |
| 2025-12-17 | HALLADAY BENJAMIN | Chief Financial Officer | Sale | 7,337 | $26,905 |
| 2025-12-04 | HARLOW JOHN B. JR. | Officer | Stock Award | 424,536 | - |
| 2025-10-17 | LOOKER BENJAMIN | General Counsel | Sale | 1,248 | $3,275 |
Wall Street Analysts
Professional analyst ratings and price targets
Past News Coverage
Recent headlines mentioning ESPR from our newsroom.